Maternal body mass index and oxytocin exposure in nulliparous women: is there an interaction associated with maternal and neonatal morbidities?

Increasing body mass index (BMI) and administered doses of oxytocin are related to maternal and neonatal morbidities. We evaluated the effect of oxytocin dosage, BMI, and their interaction on select perinatal outcomes. We retrospectively studied nulliparas with singletons ≥36 weeks' gestation w...

Full description

Saved in:
Bibliographic Details
Published in:The journal of maternal-fetal & neonatal medicine 2018-08, Vol.31 (15), p.2013-2018
Main Authors: Subramaniam, Akila, Owen, John, Campbell, Sukhkamal B, Harper, Lorie M, Fitzwater, Joseph L, Edwards, Rodney K
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increasing body mass index (BMI) and administered doses of oxytocin are related to maternal and neonatal morbidities. We evaluated the effect of oxytocin dosage, BMI, and their interaction on select perinatal outcomes. We retrospectively studied nulliparas with singletons ≥36 weeks' gestation who received oxytocin and reached the second stage of labor. Oxytocin dosage was defined by the oxytocin product ([maximum oxytocin dose] × [duration of oxytocin infusion]/100 (milliunits)). Outcomes included cesarean, postpartum hemorrhage, puerperal infection, and a composite of neonatal morbidities. Logistic regression produced odds ratios (OR) for BMI and oxytocin product. The final model included a BMI-oxytocin product interaction term. One thousand two hundred and four women met enrollment criteria. Increasing BMI was associated with longer duration from first exam to delivery and higher rates of cesarean. Oxytocin dosage increased linearly with BMI (p 
ISSN:1476-7058
1476-4954
DOI:10.1080/14767058.2017.1334046